1. Academic Validation
  2. Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer

Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer

  • J Exp Clin Cancer Res. 2021 Sep 22;40(1):297. doi: 10.1186/s13046-021-02059-6.
Chaoqun Liu  # 1 2 Zhihua Pan  # 1 2 Qian Chen  # 1 2 Zetao Chen 1 2 Weiwei Liu 1 2 Ling Wu 1 2 Muhong Jiang 1 2 Wandie Lin 1 2 Yujie Zhang 1 2 Weihao Lin 1 2 Rui Zhou 3 4 Liang Zhao 5 6
Affiliations

Affiliations

  • 1 Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • 2 Department of Pathology, Guangdong Province Key Laboratory of Molecular Tumor Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
  • 3 Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China. [email protected].
  • 4 Department of Pathology, Guangdong Province Key Laboratory of Molecular Tumor Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China. [email protected].
  • 5 Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China. [email protected].
  • 6 Department of Pathology, Guangdong Province Key Laboratory of Molecular Tumor Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China. [email protected].
  • # Contributed equally.
Abstract

Background: Chemoresistance is the major cause of chemotherapy failure in patients with colorectal Cancer (CRC). Protein tyrosine kinase 6 (PTK6) is aberrantly overexpressed in clinical CRC tissues undergoing chemotherapy. We studied if PTK6 contributed to the chemoresistance of CRC in human and mice.

Methods: We obtained tissue samples from patients with CRC and measured the expression of PTK6 by immunohistochemistry. Gain- and loss-of-function assays were performed to study the biological functions of PTK6. We constructed the FLAG-tagged wild type (WT), kinase-dead, and inhibition-defective recombinant mutants of PTK6 to study the effect phosphorylated activation of PTK6 played on CRC cell stemness and chemoresistance. We used small molecule inhibitor XMU-MP-2 to test the influence of PTK6 on sensitivity of CRC cells to 5-FU/L-OHP in both nude mouse and patient-derived xenograft (PDX) animal models.

Results: PTK6 is overexpressed in CRC tissues and plays a stimulatory role in the proliferation and chemoresistance of CRC cells both in vitro and in vivo. PTK6, especially the phosphorylated PTK6, can promote the stemness of CRC cells through interacting with JAK2 and phosphorylating it to activate the JAK2/STAT3 signaling. Pharmacological inhibition of PTK6 using XMU-MP-2 effectively reduces the stemness property of CRC cells and improves its chemosensitivity to 5-FU/L-OHP in both nude mice subcutaneously implanted tumor model and PDX model constructed with NOD-SCID mice.

Conclusions: PTK6 interacts with JAK2 and phosphorylates it to activate JAK2/STAT3 signaling to promote the stemness and chemoresistance of CRC cells. Pharmacological inhibition of PTK6 by small molecule inhibitor dramatically enhances the sensitivity to chemotherapy in nude mice and PDX models.

Keywords

Chemoresistance; Colorectal cancer; PTK6; Small molecule kinase inhibitor; Stemness.

Figures
Products